Table 4.
Studies that have analyzed allergic rhinitis as a pediatric OSA risk factor.
| Study | Year | Type of Study | Patients n° | Age | Parameters Evaluated | Conclusions |
|---|---|---|---|---|---|---|
| Cao Y. et al. [51] | 2018 | Meta-analysis (44 studies) | 6086 total patients | 47.97 (adults) 7.73 (children) |
Age and Sex; | Children with OSA suffering from a higher incidence of AR. OSA adults with AR do not have any influences on sleep parameters |
| BMI; | ||||||
| Neck circumference; | ||||||
| AHI; | ||||||
| ESS; | ||||||
| AR prevalence | ||||||
| Kheirandish-Gozal L. et al. [52] | 2014 | Retrospective review | 3071 | 2–14 | Age and Sex; | Effective alternative to adenotonsillectomy, particularly in younger and non-obese Children |
| BMI; | ||||||
| Pretreatment: AT grade; | ||||||
| Mallampati; | ||||||
| Total sleep time; | ||||||
| AHI, ODI; | ||||||
| Posttreatment: Pretreatment: AT grade; | ||||||
| Mallampati; | ||||||
| Total sleep time; | ||||||
| AHI, ODI | ||||||
| Kheirandish-Gozal L. et al. [53] | 2016 | Prospective randomized trial study | 92 | 2–10 | Age and Sex; | Beneficial effects (reduction of AHI and ODI) in 71% of children treated with montelukast. No changes in those treated with placebo. |
| BMI; | ||||||
| Pretreatment: AT grade; | ||||||
| Mallampati; | ||||||
| Total sleep time; | ||||||
| AHI, ODI; | ||||||
| Posttreatment: Pretreatment: AT grade; | ||||||
| Mallampati; | ||||||
| Total sleep time; | ||||||
| AHI, ODI | ||||||
| Brouillette R.T. et al. [54] | 2001 | Triple-blind randomized placebo-controlled trial | 25 | 1–10 | Age and Sex; | Decrease in AHI/ODI values in 12/13 of fluticasone group. No changes in placebo group |
| Pretreatment: | ||||||
| AHI, ODI; | ||||||
| Total sleep time; | ||||||
| AT grade; | ||||||
| AR symptoms | ||||||
| Posttreatment: AHI, ODI; | ||||||
| Total sleep time; | ||||||
| AT grade; | ||||||
| AR symptoms |